Lupin Limited 

(Public, BOM:500257)   Watch this stock   
Find more results for 500257
Oct 26, 2009
Q2 09/2010 LUPIN LTD Earnings Release
  

Key stats and ratios

Q3 (Sep '09) 2009
Net profit margin 14.09% 13.12%
Operating margin 15.80% 15.65%
EBITD margin - 19.89%
Return on average assets - 13.53%
Return on average equity - 37.09%
Employees 6,000 -

Address

159 CST Road Kalina Santacruz (E)
Mumbai, 400 098
India
+91-22-66402222 (Phone)
+91-22-66402130 (Fax)

Website links

Lupin Limited discussions

  View all discussions »

Description

Lupin Limited is an Indian-based pharmaceutical company. The Company develops and markets a range of generic formulations and Active Pharmaceutical Ingredients (APIs) in markets around the world. In April 2008, the Company launched suprax 400 milligram tablets (Cefixime USP) in the United States. In July 2008, the Company acquired Hormosan Pharma GmbH. In September 2008, the Company acquired a majority stake in Pharma Dynamics (PD) in South Africa. In March 2009, Lupin Limited announced the completion of acquisition of a majority stake in Multicare Pharmaceuticals Philippines, Inc.

Officers and directors

Desh Bandhu Gupta
Chairman of the Board
Nilesh Gupta
Group President, Executive Director
Vinita Gupta
Group President & CEO of Lupin Pharmaceuticals Inc., USA, Non-Executive Director
Satish Khanna
Group President - API
Shakti Chakraborty
President - India Region Formulations
Vinod Dhawan
President - AAMLA & Business Development
Harish Narula
President - Corporate Development & CIS
Naresh Gupta
President - API & Global TB
Ramesh Swaminathan
President - Finance & Planning
Ninad A. Deshpanday Ph.D.
President - Pharma Research & Development